Supplemental Tables 1-5 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy

Supplemental Table 1. Genomic alterations observed in MSK-THY1 Supplemental Table 2. Cellular prevalence of single nucleotide variants in MSK-THY Supplemental Table 3. Normalized gene expression data from patient MSK-THY1 Supplemental Table 4. Mutational data for 639 thyroid tumors sequenced by MSK-IMPACT Supplemental Table 5. Mutational data for BRAFi treated thyroid cancers with post-treatment sequencing